Monday, 25 Sep 2017

You are here

TNF Inhibitor Therapy and the Risk of Anterior Uveitis Recurrence

The TNF inhibitor drug development trials have indirectly taught us that monoclonal antibody based TNFi was capable of retarding the recurrence of anterior uveitis (AU) in patients with ankylosing spondylitis (AS).

This issue has been revisited by Swedish investigators who studied the ability of adalimumab (ADA), etanercept (ETN) and infliximab (IFX) on AU recurrence in AS patients using patients from the Swedish Rheumatology Quality Register starting their first TNFi between January 2003 to December 2010. 

The study included 1365 patients with AS.

Compared with pretreatment rates, reduced rates for AU rates were seen with ADA and IFX, while an increased AU rate was seen for ETN.

The adjusted HRs for developing AU were significantly higher for ETN versus ADA (HR: 3.86) and ETN versus IFX (HR: 1.99), while the HR for IFX versus ADA was not statistically significant.

These data confirm earlier observational studies showing the efficacy of ADA and IFX in AU. However, this study suggests little or no protection when using ETN. Suggesting mechanistic differences between antibody and receptor based therapies are clinically important in this particular extraspinal manifestation of AS.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Psoriasis Doubles Mortality Risk

Noe and colleagues have reported in the Journal of Investigative Dermatology that by estimating the extent of skin involvement in psoriasis (%BSA) they may assess future mortality risk. 

Psoriasis patients with 10% or more body surface area (BSA) involvement nearly doubled their risk of early death than those without the disease.

IV Golimumab Shines in Psoriatic Arthritis

Golimumab (GOL) is one of five marketed TNF inhibitors (TNFi) that is FDA approved for use in psoriatic arthritis (PsA). PsA approval was based on a 259 patient, randomized, controlled trial wherein GOL treated patients exhibited at week 24 ACR20/50/70 response of 52%, 32%, and 19%, respectively.

Therapeutic Update: 5 Questions on FDA Hearing for Tofacitinib in PsA

In this Therapeutic Update, Drs. Mease, Gibofsky and Cush answer five questions regarding the August 3rd FDA Arthritis Advisory Committee meeting that reviewed the potential approval of tofacitinib (Xeljanz) in patients with active psoriatic arthritis. The panel was nearly unanimous (10-1) in favor of the efficacy and safety profile of of tofacitinib, and similarly voted 10-1 to approve this drug for use in PsA. Final decisions on these recommendations from the AAC panel will be made at a later date by the FDA. 

Psoriatic Arthritis Patients with Comorbidities have Worse Disease and Poor Responses

A population-based cohort study shows that comorbidities in psoriatic arthritis patients (PsA) were associated with higher disease activity, shorter persistence and reduced clinical response to TNF inhibitors (TNFi). 

FDA Arthritis Advisory Panel Endorses Tofacitinib Approval for Psoriatic Arthritis

On Thursday, August 3, the FDA Arthritis Advisory Committee (AAC) met to consider tofacitinib for use in patients with psoriatic arthritis. The panel voted 10-1 in favor of approval.